O

Orchestra Biomed Holdings Inc
NASDAQ:OBIO

Watchlist Manager
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Watchlist
Price: 2.66 USD -2.21% Market Closed
Market Cap: 101.9m USD

Wall Street
Price Targets

OBIO Price Targets Summary
Orchestra Biomed Holdings Inc

Wall Street analysts forecast OBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OBIO is 13.84 USD with a low forecast of 12.12 USD and a high forecast of 21 USD.

Lowest
Price Target
12.12 USD
356% Upside
Average
Price Target
13.84 USD
420% Upside
Highest
Price Target
21 USD
689% Upside
Orchestra Biomed Holdings Inc Competitors:
Price Targets
2291
Lepu Scientech Medical Technology Shanghai Co Ltd
13% Upside
FPH
Fisher & Paykel Healthcare Corporation Ltd
1% Upside
IRMD
IRadimed Corp
6% Upside
MEDX
Medmix Ltd
78% Upside
228850
Rayence Co Ltd
31% Upside
301363
Mehow Innovative Ltd
37% Upside
SOON
Sonova Holding AG
21% Upside
9996
Peijia Medical Ltd
19% Downside

Revenue
Forecast

Revenue Estimate
Orchestra Biomed Holdings Inc

The compound annual growth rate of Orchestra Biomed Holdings Inc's revenue for the next 3 years is 11%.

N/A
Past Growth
11%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Orchestra Biomed Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Orchestra Biomed Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-16%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OBIO's stock price target?
Price Target
13.84 USD

According to Wall Street analysts, the average 1-year price target for OBIO is 13.84 USD with a low forecast of 12.12 USD and a high forecast of 21 USD.

What is Orchestra Biomed Holdings Inc's Revenue forecast?
Projected CAGR
11%

The compound annual growth rate of Orchestra Biomed Holdings Inc's revenue for the next 3 years is 11%.

Back to Top